[Protective effect of angiotensin coverting enzyme inhibitor on renal function in normotensive non-insulin dependent diabetes mellitus patients with early diabetic nephropathy and microalbuminuria]
- PMID: 9594145
[Protective effect of angiotensin coverting enzyme inhibitor on renal function in normotensive non-insulin dependent diabetes mellitus patients with early diabetic nephropathy and microalbuminuria]
Abstract
Fourty six cases of non-insulin dependent diabetes mellitus (NIDDM) with normotension and microalbuminuria (< 30 mg/24 h) were divided into groups A and B, and observed for about 2 years. Only group A was treated with perindopril 2 mg a day. We found that 2 years later glomerular filtration rate (GFR), effective renal plasma flow (ERPF) and filtration fraction (FF) in the two groups decreased markedly, but GFR and FF decreased more markedly in group B than in group A. Meanwhile, in group A urinary albumin excretion rate (UAER) and insulin sensitivity index (SI) decreased significantly and blood pressure was stable, but in group B UAER and blood pressure elevated significantly and SI was only slightly ameliorated (P > 0.05). The levels of serum triglycerides and cholesterol were not markedly different between the two groups during the 2 years. These results indicate that ACEI may play a role in protecting the renal function in diabetic nephropathy, reduce the risk factors of atherosclerosis and improve SI. It is beneficial to retard the development of diabetic nephropathy and to protect in renal function with small dose of ACEI.
Similar articles
-
Renal autoregulation is normal in newly diagnosed, normotensive, NIDDM patients.Diabetologia. 1998 Feb;41(2):206-11. doi: 10.1007/s001250050891. Diabetologia. 1998. PMID: 9498655 Clinical Trial.
-
Low-dose angiotensin converting enzyme inhibitors: effect on renal function in normo- and hypertensive type 1 diabetic patients.Eur J Med. 1992 Sep;1(5):268-72. Eur J Med. 1992. PMID: 1341608 Clinical Trial.
-
Renal function, glycemic control and perindopril in diabetic patients.Clin Exp Hypertens A. 1989;11 Suppl 2:545-54. Clin Exp Hypertens A. 1989. PMID: 2691128 Clinical Trial.
-
Renal protection and angiotensin converting enzyme inhibition in microalbuminuric type I and type II diabetic patients.J Hypertens Suppl. 1996 Dec;14(6):S11-4. J Hypertens Suppl. 1996. PMID: 9023709 Review.
-
Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study.Acta Diabetol. 2005 Apr;42 Suppl 1:S42-9. doi: 10.1007/s00592-005-0180-4. Acta Diabetol. 2005. PMID: 15868119 Review.
Cited by
-
Angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic kidney disease.Cochrane Database Syst Rev. 2024 Apr 29;4(4):CD006257. doi: 10.1002/14651858.CD006257.pub2. Cochrane Database Syst Rev. 2024. PMID: 38682786 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical